Progenesis logo
Progenesis is a San Diego-based company founded in 2015 that develops and offers non-invasive genetic tests for patients on their family planning journey. We offer a variety of services that can be customized to meet the needs of every patient we serve. The Progenesis team is a motivated group of genetic specialists, researchers, laboratory professionals, and analysts who are passionate about improving our patients' lives. As pioneers in genetic screening technologies, our scientists are constantly pursuing research initiatives to advance our services and expand our understanding of human genetics.
side-area-image-1
Address: 4150 Regents Park Row Suite 245 La Jolla, CA 92037

Email: info@progenesis.com
Phone: (858) 257-2122
Fax: (858) 469-8600

Author: admin

Last week, Progenesis CEO, Dr. Nabil Arrach, joined other experts in assisted reproductive technology to discuss the recent Fertility and Sterility publication, "Pushing the limits of detection: investigation of cell-free DNA for aneuploidy screening in embryos." The discussion took place via the Fertility and Sterility online Journal Club and was streamed live to viewers on Thursday, November 15th. If you weren't able to tune in for the...

Read More

Progenesis is dedicated to innovation in reproductive health. As such, our expert scientists are constantly working to improve our products and practices through research and development. We recently collaborated on a study investigating the use of cell-free DNA for aneuploidy screening in embryos. The manuscript detailing this study, "Pushing the limits of detection: investigation of cell-free DNA for aneuploidy screening in embryos," was published in the...

Read More

Progenesis, Inc is excited to present at the Inducción de Ovulación y Manejo de Consultorio de la Infertilidad workshop this Friday, October 26, 2018, in Tijuana, Mexico. Our own Dr. Nabil Arrach, CEO, will be sharing his expertise about genetic diagnostics in the reproductive field. Specifically, Dr. Arrach will be addressing: Best practices for embryo biopsy and PGT-A testing Current challenges in PGT-A testing Future...

Read More

La Jolla, CA — October 17, 2018 — Progenesis, Inc, an industry leader in reproductive genetics, announced today that its clinical laboratory has received accreditation from the College of American Pathologists (CAP), meeting the highest standard of excellence in clinical laboratory practices. This accreditation comes after successful completion of the CAP inspection process and adds Progenesis, Inc, to an elite group of laboratories that operate at...

Read More

Preimplantation Genetic Diagnosis Preimplantation Genetic Testing for Monogenic/Single Gene Defects (PGT-M) is a technique used by specialized medical laboratories to select embryos not found to carry specific genetic disorders prior to their transfer into a woman’s womb. It is also known as Preimplantation Genetic Diagnosis (PGD). Why is PGT-M used? PGT-M is normally used in an attempt to eliminate the risk of passing a specific genetic disorder from the parents to their child....

Read More

For the past few years, the use of array comparative genome hybridization (aCGH) offered a substantial improvement in preimplantation genetic screening (PGS), increasing the number of tested chromosomes from a handful to 24 chromosomes. Unfortunately, this seemingly improved technology came at a cost since aCGH is estimated to have at least 2% error rate. What makes array CGH prone to errors? Array CGH is an indirect measurement as it relies on...

Read More